Ekso Bionics (NASDAQ:EKSO) Major Shareholder Daniel Asher Buys 15,540 Shares

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) major shareholder Daniel Asher purchased 15,540 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were bought at an average price of $12.30 per share, with a total value of $191,142.00. Following the purchase, the insider directly owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. The trade was a 6.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ekso Bionics Stock Performance

NASDAQ:EKSO traded down $1.12 during midday trading on Friday, reaching $11.18. The stock had a trading volume of 131,128 shares, compared to its average volume of 291,404. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The stock has a market cap of $29.29 million, a P/E ratio of -1.97 and a beta of 0.80. The firm has a fifty day simple moving average of $8.17 and a two-hundred day simple moving average of $5.69. Ekso Bionics Holdings, Inc. has a 12-month low of $2.73 and a 12-month high of $13.27.

Institutional Investors Weigh In On Ekso Bionics

A number of large investors have recently added to or reduced their stakes in the business. Consolidated Portfolio Review Corp purchased a new position in shares of Ekso Bionics during the third quarter valued at approximately $333,000. Citadel Advisors LLC purchased a new stake in Ekso Bionics in the 3rd quarter worth approximately $198,000. Shay Capital LLC acquired a new position in Ekso Bionics in the 3rd quarter valued at $67,000. Virtu Financial LLC purchased a new position in shares of Ekso Bionics during the 3rd quarter worth $57,000. Finally, Geode Capital Management LLC lifted its stake in shares of Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after purchasing an additional 10,281 shares during the period. 6.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on EKSO shares. HC Wainwright cut shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Wall Street Zen upgraded Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ekso Bionics has a consensus rating of “Hold” and a consensus price target of $10.50.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.